HomeCompareELEMF vs ABBV

ELEMF vs ABBV: Dividend Comparison 2026

ELEMF yields 10.41% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $80.8K in total portfolio value
10 years
ELEMF
ELEMF
● Live price
10.41%
Share price
$19.22
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.5K
Annual income
$1.11
Full ELEMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ELEMF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELEMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELEMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELEMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELEMF
Annual income on $10K today (after 15% tax)
$884.50/yr
After 10yr DRIP, annual income (after tax)
$0.94/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELEMF + ABBV for your $10,000?

ELEMF: 50%ABBV: 50%
100% ABBV50/50100% ELEMF
Portfolio after 10yr
$61.9K
Annual income
$12,386.44/yr
Blended yield
20.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ELEMF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
71.0
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELEMF buys
0
ABBV buys
0
No recent congressional trades found for ELEMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELEMFABBV
Forward yield10.41%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$21.5K$102.3K
Annual income after 10y$1.11$24,771.77
Total dividends collected$1.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: ELEMF vs ABBV ($10,000, DRIP)

YearELEMF PortfolioELEMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,220$520.29$11,550$430.00$330.00ABBV
2$12,279$272.80$13,472$627.96$1.2KABBV
3$13,277$139.50$15,906$926.08$2.6KABBV
4$14,277$70.49$19,071$1,382.55$4.8KABBV
5$15,312$35.42$23,302$2,095.81$8.0KABBV
6$16,402$17.75$29,150$3,237.93$12.7KABBV
7$17,559$8.88$37,536$5,121.41$20.0KABBV
8$18,792$4.44$50,079$8,338.38$31.3KABBV
9$20,110$2.22$69,753$14,065.80$49.6KABBV
10$21,519$1.11$102,337$24,771.77$80.8KABBV

ELEMF vs ABBV: Complete Analysis 2026

ELEMFStock

Elemental Royalties Corp., a gold-focused royalty company, engages in the evaluation and acquisition of royalties. It has a portfolio of nine royalties in Chile, Western Australia, Kenya, Canada, Mexico, and Burkina Faso. The company is headquartered in Vancouver, Canada.

Full ELEMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ELEMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELEMF vs SCHDELEMF vs JEPIELEMF vs OELEMF vs KOELEMF vs MAINELEMF vs JNJELEMF vs MRKELEMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.